University of Connecticut (UConn)
In July 2018, INHIBITOR entered into a world-wide option agreement concerning itraconazole analogues, which are being developed by Dr. M. Kyle Hadden, Associate Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences at UConn. These analogues have modifications to particular regions of the itraconazole scaffold. There are patents and patent applications which include compositions of matter claims covering the itraconazole analogues and method claims covering their use for the treatment of cancer.